Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.

HR gene mutational status was associated with comparable clinical outcomes following treatment with ARSIs or taxane-based chemotherapy. Additional prospective studies are needed to confirm these findings.